TY - JOUR T1 - Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events after Hospitalization: Findings from ASSESS-AKI and ARID studies JF - medRxiv DO - 10.1101/2021.11.08.21266015 SP - 2021.11.08.21266015 AU - Steven G. Coca AU - George Vasquez-Rios AU - Sherry G. Mansour AU - Dennis G. Moledina AU - Heather Thiessen-Philbrook AU - Mark M. Wurfel AU - Jonathan Himmelfarb AU - Eddie Siew AU - Amit X. Garg AU - Chi-yuan Hsu AU - Kathleen D. Liu AU - Paul L. Kimmel AU - Vernon M. Chinchilli AU - James S. Kaufman AU - Michelle Wilson AU - Rosamonde E Banks AU - Rebecca Packington AU - Eibhlin McCole AU - Mary Jo Kurth AU - Ciaran Richardson AU - Alan S. Go AU - Nicholas M Selby AU - Chirag R. Parikh Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/10/2021.11.08.21266015.abstract N2 - Background The role of plasma soluble tumor necrosis factor receptor (sTNFR)1 and sTNFR2 in the prognosis of clinical events after hospitalization with or without acute kidney injury (AKI) is unknown.Methods We measured sTNFR1 and sTNFR2 obtained 3 months post-discharge using samples from Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) and AKI Risk in Derby (ARID) that enrolled patients with and without AKI. The associations between biomarkers with longitudinal kidney disease incidence and progression, heart failure and death were evaluated. Analyses were adjusted for demographics and key covariates at the 3-month visit.Results Among 1474 participants with plasma biomarker measurements, 19% developed kidney disease progression, 14% had later heart failure, and 21% died over a median follow-up of 4.4 years. For the kidney outcome, the adjusted HRs per doubling in concentration were 2.9 (2.2-3.9) for sTNFR1 and 1.9 (1.5-2.5) for sTNFR2. AKI during the index hospitalization did not modify the association between biomarkers and kidney events. For heart failure, the adjusted HRs per doubling in concentration were 1.9 (1.4-2.5) for sTNFR1 and 1.5 (1.2-2.0) for sTNFR2. For mortality, the adjusted HRs were 3.3 (2.5-4.3) for sTNFR1 and 2.5 (2.0-3.1) for sTNFR2. The findings in ARID were qualitatively similar for the magnitude of association between biomarkers and outcomes.Conclusion Plasma sTNFR1 and sTNFR2 measured 3 months after discharge were independently associated with clinical events, regardless of AKI status during the index admission. sTNFR1 and sTNFR2 may assist with the risk stratification of patients during follow-up.Significance Statement Soluble tumor necrosis factor receptor 1 (sTNFR1) and sTNFR2 associate with kidney outcomes in patients with chronic kidney disease with and without diabetes mellitus. However, their role in the post-hospitalization stage is unknown. High sTNFR1 and sTNFR2 obtained 3 months after discharge associate with kidney events, heart failure hospitalizations, and death among patients who did and did not have acute kidney injury (AKI). Furthermore, sTNFRs provide discriminative value at the time of predicting kidney events. These findings were demonstrated in two large independent prospective cohorts. sTNFR1 and sTNFR2 may detect patients at risk of future adverse events even when patients do not meet the clinical criteria for AKI or exhibit biochemical abnormalities.Competing Interest StatementSGC has salary support from NIH grants R01DK115562 UO1DK106962 R01HL085757 R01DK112258 R01DK126477 and UH3DK114920 SGC reports personal income and equity and stock options from Renalytix and pulseData He also reports personal income from Axon Therapeutics Bayer Boehringer Ingelheim CHF Solutions ProKidney Vifor and Takeda EDS reports personal income from Akebia Therapeutics Da Vita and UpToDate He also serves as an associate editor for the Clinical Journal of the American Society of Nephrology DGM is supported by an NIH K23 grant K23DK117065 and by the Yale O Brien Kidney Center P30DK079310 SGM is supported by AHA 18CDA34110151 the Yale O Brien Kidney Center and the Patterson Trust Fund NIH R01HL085757 to CRP funded the TRIBE AKI Consortium PLK reports being an editor of the textbook Chronic Renal Disease and the monograph Psychosocial Aspects of Chronic Kidney Disease CRP is supported by NIH grant K24DK090203 and the P30DK079310 O Brien Kidney Center Grant CRP reports personal income and equity and stock options from Renaltyix He also reports personal income from Genfit Biopharmaceutical Company and Akebia Therapeutics EM CR and MJK are employees of Randox but do not own shares in the company The remaining authors declare that they have no relevant financial interests The authors would like to thank all of the ASSESS AKI study participants for making this study possible The ASSESS-AKI was supported by cooperative agreements from the NIDDK U01DK082223 U01DK082185 U01DK082192 and U01DK082183 We also acknowledge funding support from NIH grants R01HL085757 R01DK098233 R01DK101507 R01DK114014 K23DK100468 R03DK111881 R01DK093771 K01DK120783 P30DK079310 and P30DK114809 The ARID study was funded by a grant from Kidney Research UK RP13/2015 The ARID study would like to acknowledge the support provided by John Lamont and Peter FitzGerald from Randox Laboratories LtdClinical Protocols https://repository.niddk.nih.gov/studies/assess-aki/ Funding StatementThe ASSESS-AKI was supported by cooperative agreements from the NIDDK (U01DK082223, U01DK082185, U01DK082192, and U01DK082183). We also acknowledge funding support from NIH grants R01HL085757, R01DK098233, R01DK101507, R01DK114014, K23DK100468, R03DK111881, R01DK093771, K01DK120783, P30DK079310, and P30DK114809. The ARID study was funded by a grant from Kidney Research UK (RP13/2015). The funder did not have any role in study design, data collection, analysis, reporting, or the decision to submit for publication. The ARID study would like to acknowledge the support provided by John Lamont and Peter FitzGerald from Randox Laboratories Ltd. The results opinions expressed in this paper do not necessarily reflect those of the National Institute of Diabetes Digestive and Kidney Diseases, the National Institutes of Health, the Department of Health, and Human Services, or the government of the United States.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee/IRB of the University of Washington gave ethical approval for this work. The ethics committee/IRB of Yale University gave ethical approval for this work. The ethics committee/IRB of Kaiser Permanente gave ethical approval for this work. The ethics committee/IRB of Vanderbilt University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://repository.niddk.nih.gov/studies/assess-aki/ ER -